These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 11070372)

  • 1. Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke.
    Muir KW; Holzapfel L; Lees KR
    Cerebrovasc Dis; 2000; 10(6):431-6. PubMed ID: 11070372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions.
    Hussein Z; Fraser IJ; Lees KR; Muir KW; Lunnon MW; Hobbiger SF; Posner J
    Br J Clin Pharmacol; 1996 Jun; 41(6):505-11. PubMed ID: 8799514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of 619C89 after acute stroke.
    Muir KW; Hamilton SJ; Lunnon MW; Hobbiger S; Lees KR
    Cerebrovasc Dis; 1998; 8(1):31-7. PubMed ID: 9645979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study.
    Diener HC; AlKhedr A; Busse O; Hacke W; Zingmark PH; Jonsson N; Basun H;
    J Neurol; 2002 May; 249(5):561-8. PubMed ID: 12021946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neuroprotective agent sipatrigine blocks multiple cardiac ion channels and causes triangulation of the ventricular action potential.
    Gao Z; Milnes JT; Choisy SC; Leach MJ; Hancox JC; James AF
    Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1088-96. PubMed ID: 16445575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiology of sipatrigine: a lamotrigine derivative exhibiting neuroprotective effects.
    Calabresi P; Stefani A; Marfia GA; Hainsworth AH; Centonze D; Saulle E; Spadoni F; Leach MJ; Giacomini P; Bernardi G
    Exp Neurol; 2000 Mar; 162(1):171-9. PubMed ID: 10716897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke.
    Muir KW; Lees KR; Hamilton SJ; George CF; Hobbiger SF; Lunnon MW
    Ann N Y Acad Sci; 1995 Sep; 765():328-9. PubMed ID: 7486634
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients: a dose-ranging study.
    Lees KR; Dyker AG; Sharma A; Ford GA; Ardron ME; Grosset DG
    Stroke; 2001 Feb; 32(2):466-72. PubMed ID: 11157184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium channel blocking activity of AM-36 and sipatrigine (BW619C89): in vitro and in vivo evidence.
    Callaway JK; Castillo-Melendez M; Giardina SF; Krstew EK; Beart PM; Jarrott B
    Neuropharmacology; 2004 Jul; 47(1):146-55. PubMed ID: 15165842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tolerability, pharmacokinetics and pharmacodynamics of increasing intravenous doses of 619C89, a novel compound for the acute treatment of stroke, in healthy volunteers.
    Mercer AJ; Lamb RJ; Hussein Z; Hobbiger S; Posner J
    Ann N Y Acad Sci; 1995 Sep; 765():324-6. PubMed ID: 7486632
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen.
    Kaste M; Murayama S; Ford GA; Dippel DW; Walters MR; Tatlisumak T;
    Cerebrovasc Dis; 2013; 36(3):196-204. PubMed ID: 24135530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sipatrigine could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1.
    Tsai SJ
    Med Hypotheses; 2008; 70(3):548-50. PubMed ID: 17703894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sipatrigine and oligodendrocyte and axonal pathology following transient focal cerebral ischaemia in the rat.
    McCracken E; Dewar D; McCulloch J
    Neuroreport; 2003 Mar; 14(3):517-20. PubMed ID: 12634515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NXY-059 for acute ischemic stroke.
    Lees KR; Zivin JA; Ashwood T; Davalos A; Davis SM; Diener HC; Grotta J; Lyden P; Shuaib A; Hårdemark HG; Wasiewski WW;
    N Engl J Med; 2006 Feb; 354(6):588-600. PubMed ID: 16467546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.
    Lang W; Stadler CH; Poljakovic Z; Fleet D;
    Int J Stroke; 2013 Feb; 8(2):95-104. PubMed ID: 23009193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.
    Heiss WD; Brainin M; Bornstein NM; Tuomilehto J; Hong Z;
    Stroke; 2012 Mar; 43(3):630-6. PubMed ID: 22282884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ginsenoside-Rd improves outcome of acute ischaemic stroke - a randomized, double-blind, placebo-controlled, multicenter trial.
    Liu X; Wang L; Wen A; Yang J; Yan Y; Song Y; Liu X; Ren H; Wu Y; Li Z; Chen W; Xu Y; Li L; Xia J; Zhao G
    Eur J Neurol; 2012 Jun; 19(6):855-63. PubMed ID: 22233205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
    Hacke W; Albers G; Al-Rawi Y; Bogousslavsky J; Davalos A; Eliasziw M; Fischer M; Furlan A; Kaste M; Lees KR; Soehngen M; Warach S;
    Stroke; 2005 Jan; 36(1):66-73. PubMed ID: 15569863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT).
    Teal P; Davis S; Hacke W; Kaste M; Lyden PD; ; Fierus M;
    Stroke; 2009 Nov; 40(11):3518-25. PubMed ID: 19745176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prehospital use of magnesium sulfate as neuroprotection in acute stroke.
    Saver JL; Starkman S; Eckstein M; Stratton SJ; Pratt FD; Hamilton S; Conwit R; Liebeskind DS; Sung G; Kramer I; Moreau G; Goldweber R; Sanossian N;
    N Engl J Med; 2015 Feb; 372(6):528-36. PubMed ID: 25651247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.